Trump selects Emmy-winning TV personality Dr. Oz to head CMS

Building on last week’s news that president-elect Donald Trump will nominate vaccine skeptic and controversial health activist Robert F. Kennedy Jr. (RFK) as secretary of Health and Human Services, it appears television personality Mehmet Oz, MD—better known as Dr. Oz—may be taking over the Centers for Medicare & Medicaid Services (CMS).

If confirmed by the U.S. Senate to the position of CMS administrator, Oz will have a leadership role in shaping Medicare and Medicaid programs, as well as the direction of health plans subsidized by the Affordable Care Act and sold on the federal government’s online marketplace. 

As with RFK, Trump announced the appointment of Oz on Truth Social, writing that Oz will be a “leader in incentivizing disease prevention.”

“America is facing a healthcare crisis, and there may be no physician more qualified and capable than Dr. Oz to Make America Healthy Again,” Trump wrote in the post. “Dr. Oz will work closely with Robert F. Kennedy Jr. to take on the illness industrial complex, and all the horrible chronic disease left in its wake.”

Rise to Fame

Oz is a cardiothoracic surgeon who received his medical degree from the University of Pennsylvania. However, his rise to fame came in 1996 when he and doctors at Presbyterian Hospital in New York City successfully performed a heart transplant on Frank Torre, brother of Joe Torre, the manager of the New York Yankees. 

His public notoriety landed him a recurring role on Oprah Winfrey’s daytime talk show in 2004, serving as the show’s “health expert” on a variety of topics. He began hosting his own daytime talk show, "the Dr. Oz Show", in 2009. Oz would go on to win nine Emmy awards.

His show remained on the air until 2022, the same year Oz ran for the U.S. Senate from Pennsylvania as a Republican, ultimately losing the election to Democrat John Fetterman. 

Oz’s connection to Trump was solidified during the COVID-19 pandemic, where the TV doctor questioned the touted benefits of COVID lockdowns and other policies. He also advocated for the emergency use of hydroxychloroquine as a treatment for the virus, with reporters pointing out a potential conflict of interest due to his ownership of stock in companies that manufacture the drug. 

If confirmed as CMS administrator, Oz will replace Chiquita W. Brooks-LaSure, who has been in the role since May 2021. 

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.